Reported Regression of ALD Complications After Sustained Abstinence

Sustained alcohol abstinence was described as being associated with hepatic recompensation in a subset of patients with previously decompensated alcohol-related cirrhosis, based on reported multicenter retrospective observational results.

The report describes a cohort of 633 patients across 17 specialist centers in Europe and Asia, enrolled at the time abstinence was achieved in a decompensated disease stage. Hepatic recompensation was defined using Baveno VII criteria, requiring sustained abstinence (≥3 months), resolution of ascites and hepatic encephalopathy off therapy, absence of variceal bleeding for one year, and restored liver function (Child-Pugh A or MELD <10). About one third of patients reached recompensation within five years.

Alongside baseline disease severity, the likelihood of achieving recompensation was linked to early abstinence (within one month of index decompensation) and the absence of further decompensation at the time abstinence was achieved. Overall, the report frames these points as investigator interpretations of observed relationships between abstinence timing and the recompensated clinical course.

For outcomes, the report states that among recompensated patients who remained abstinent, none had liver-related deaths during follow-up. It also reports that hepatocellular carcinoma (HCC) occurred in 16 patients overall, but did not occur in any recompensated patient, which the authors describe as a negligible residual risk of HCC when abstinence is maintained. The reporting characterizes recompensation as a clinically relevant state that can shift prognosis even in advanced cirrhosis, situating these observations within broader discussions of trajectories and prognosis in alcohol-related cirrhosis.

In parallel with the clinical observations, the report characterizes complete and sustained abstinence as a central therapeutic focus in alcohol-related liver disease and notes that multidisciplinary support to achieve and maintain abstinence is important for prognosis.

Key Takeaways:

• In the multicenter cohort, hepatic recompensation was defined by Baveno VII criteria (including sustained abstinence ≥3 months, resolution of ascites/encephalopathy off therapy, no variceal bleeding for one year, and restored liver function) and was reported to occur in about one third of patients within five years.
• The study links recompensation to early abstinence (within one month of decompensation) and absence of further decompensation at abstinence.
• Among the recompensated subgroup that remained abstinent, the report describes a negligible residual risk of liver-related death and HCC, noting that no recompensated abstinent patient had liver-related death and no HCC occurred in recompensated patients during follow-up.